Transcode Therapeutics annual return on equity
2021
2022
2023
2025
Transcode Therapeutics Return on Equity (ROE) Growth & History (RNAZ)
Transcode Therapeutics's return on equity was −833.53% for fiscal 2025.
View full Transcode Therapeutics company overviewTranscode Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −833.53% | — |
| 2023 | 2023-12-31 | −759.85% | −611.28 pp |
| 2022 | 2022-12-31 | −148.57% | −68.04 pp |
| 2021 | 2021-12-31 | −80.53% | — |
Transcode Therapeutics quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | −306.99% | −14.85 pp |
| Q4 2025 | 2025-12-31 | −228.60% | — |
| Q3 2025 | 2025-09-30 | −128.23% | +27.85 pp |
| Q2 2025 | 2025-06-30 | −52.02% | +123.74 pp |
| Q1 2025 | 2025-03-31 | −292.13% | −185.25 pp |
| Q3 2024 | 2024-09-30 | −156.09% | +6.18 pp |
| Q2 2024 | 2024-06-30 | −175.76% | +292.17 pp |
| Q1 2024 | 2024-03-31 | −106.88% | +213.83 pp |
| Q4 2023 | 2023-12-31 | −134.44% | −45.04 pp |
| Q3 2023 | 2023-09-30 | −162.27% | −120.77 pp |
| Q2 2023 | 2023-06-30 | −467.93% | −436.19 pp |
| Q1 2023 | 2023-03-31 | −320.71% | −302.16 pp |
| Q4 2022 | 2022-12-31 | −89.41% | −76.55 pp |
| Q3 2022 | 2022-09-30 | −41.50% | −15.79 pp |
| Q2 2022 | 2022-06-30 | −31.75% | — |
| Q1 2022 | 2022-03-31 | −18.55% | — |
| Q4 2021 | 2021-12-31 | −12.85% | — |
| Q3 2021 | 2021-09-30 | −25.72% | — |
Transcode Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Transcode Therapeutics's return on equity decreased from −80.53% to −833.53%, a change of −753.00 percentage points. The latest reported quarter, Q1 2026, shows −306.99%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Transcode Therapeutics source filings ↗